No Data
No Data
Yasheng Pharmaceuticals has also landed | JIANZHI Research
One step closer to regular profitability.
Ascentage Pharma Turns to H1 Profit as Revenue Balloons 477%; Shares Jump 4%
Hong Kong stock market | Aisino Medicine-B (06855) rose more than 4% after the performance, with a year-on-year revenue increase of more than 4.7 times in the first half of the year, and the company's cash flow remained strong and abundant.
As of the time of writing, Ali Health-B (06855) rose more than 4% after the performance announcement, with an increase of 4.13%, reaching HK$29, with a turnover of HK$9.569 million.
First-time turn of profit! Yasheng Medicine (6855.HK) released an impressive interim report, with heavyweight collaborations propelling a new stage of internationalization.
On August 22, 2024, Asia Pharmaceutical (6855.HK) released its mid-year 2024 performance, achieving a record high revenue in the first half of the year, reaching RMB 0.824 billion, a 477% year-on-year increase compared to last year, mainly from product sales revenue and external cooperation authorization revenue. The company achieved semi-annual profitability for the first time, with a net income of RMB 0.163 billion. The announcement shows that the company's cash flow continues to improve and remains robust. As of early July 2024, the balance of monetary funds is RMB 1.8 billion. Asia Pharmaceutical's first listed variety, Orlottinib (trade name: Naitric), is rapidly commercializing.
Yasheng Pharmaceuticals -B (06855) welcomes its first-ever profit in the mid-year performance, with a year-on-year revenue increase of 477%.
On August 22, 2024, Aisheng Medicine-B (06855) released its 2024 interim performance, with the company's total revenue reaching a new high in the first half of the year and achieving a profit for the first time.
Express News | Ascentage Pharma Group International H1 Net Income HKD 163 Million
No Data